PeptidePedia The community reference

Cold chain (revision 26)

Old revision·13:06, 8 Oct 2024·ComparisonCato

This is an old revision of this page, as it stood at 13:06, 8 Oct 2024, saved by ComparisonCato with the summary add citation for the incidence figure. It may differ substantially from the current revision, and any error it contains may since have been corrected.
Cold chain
Synthesis25°−2025°Air15°Customs12°2–8Endtemperature exposure along the chaina single excursion above 25 °C is enough to force re-testing
A cold chain is a series of custody transfers, each of which is a candidate point of failure and each of which is expected to leave a temperature record.
ScopeManufacture, warehousing, freight, last mile, end use
Principal controlled variableTemperature
Principal monitoring deviceElectronic temperature data logger
Principal documented outputA continuous temperature record with custody points
Storage definitions, USP <659>
Freezer−25 to −10 °C
Cold2–8 °C
Cool8–15 °C
Controlled room temperature20–25 °C; mean kinetic temperature not above 25 °C
Warm30–40 °C
Topic infobox · conventions

A cold chain is an unbroken sequence of temperature-controlled storage, handling and transport operations that maintains a temperature-sensitive product within its labelled storage conditions from the point of manufacture to the point of use. The term is used both for the physical arrangement — refrigerated rooms, insulated shippers, coolant, vehicles — and for the documentary system of records and custody transfers that demonstrates the arrangement worked.[1]

The concept originates in vaccine distribution, where it was developed from the 1970s onward as part of expanded immunisation programmes, and it retains much of that vocabulary. It has since been generalised to any product whose labelled storage conditions are narrower than ambient, including insulin and the GLP-1 receptor agonists, most of which are labelled for storage at 2–8 °C before first use.[2]

Two properties distinguish a cold chain from ordinary logistics. It is a chain in the strict sense that its integrity is set by its weakest link rather than by an average: an hour on an unshaded loading dock is not offset by a week of correct refrigeration. And its principal failure is invisible on inspection, because temperature-mediated degradation of a peptide or protein product generally produces no visible change. This combination is why monitoring instrumentation, rather than examination of the product, carries the evidentiary burden.[3]

The commonest documented failure of pharmaceutical cold chains is not overheating but inadvertent freezing. Systematic reviews of vaccine distribution have repeatedly found freezing exposure in the majority of studies examining shipments and storage, in high-income and low-income settings alike, and have identified it as more prevalent than heat exposure. Freezing is more damaging than mild warming for many liquid biological products and is not detectable after the fact by inspection.[4][5]

Storage classes and their definitions

[edit]

Labelled storage statements draw on compendial definitions rather than on plain language, and the definitions are narrower than everyday usage suggests. USP General Chapter <659> defines the terms used on United States labelling, and the European Pharmacopoeia and WHO guidance use closely comparable ranges.[6][1]

Compendial storage terms
!TermRangeNotes
Freezer−25 to −10 °CNot the same as a domestic freezer, which may run colder
Cold2–8 °CThe range meant by "refrigerated" on a label
Cool8–15 °CSeldom used on modern labelling
Controlled cold temperature2–8 °C, with permitted excursions between −20 and 25 °CExcursions are bounded in duration and by mean kinetic temperature
Controlled room temperature20–25 °C, excursions 15–30 °C permitted, mean kinetic temperature not above 25 °CThe permitted excursion band is part of the definition
Warm30–40 °C
Excessive heatabove 40 °C

Two features of this table are consequential and routinely missed. Controlled room temperature is not a synonym for whatever temperature a room happens to be; it is a specification with a permitted excursion band and a mean kinetic temperature ceiling, and a warehouse that averages 27 °C does not satisfy it. And the definitions of controlled cold and controlled room temperature both build permitted excursions into the definition itself, so a brief departure from the nominal band is not automatically an excursion in the regulatory sense — a distinction developed at Temperature excursion.[6]

Storage statements for the compounds covered on this wiki cluster in two groups. Manufactured injectable GLP-1 receptor agonists are labelled for cold storage before first use, with an in-use period at higher temperature after first use. Lyophilised research peptides are commonly accompanied by a recommendation of frozen or cold storage for long-term holding and a statement that the dry material tolerates ambient transit, a combination whose physical basis is set out at Lyophilisation and whose evidential basis is generally absent.[7]

The World Health Organization additionally defines a controlled temperature chain for specified vaccines, permitting a single excursion to ambient temperatures up to 40 °C for a defined period immediately before administration, subject to product-specific stability data and to a monitoring device that records the exposure. It is a deliberate, evidence-supported relaxation of the 2–8 °C requirement rather than a tolerance of failure, and it illustrates that cold-chain requirements are properties of products rather than of logistics.[3]

Monitoring instrumentation

[edit]

A cold chain produces a record, and the instrument that produces it determines what the record can support.

Electronic data loggers are the reference instrument for shipments and for storage. A logger samples a thermistor or thermocouple at a fixed interval, stores time-stamped values in non-volatile memory, and reports either on retrieval or, in connected variants, in near real time. What matters for interpretation is the sampling interval, the accuracy and its temperature dependence, the calibration status, and whether the sensor is in the payload or in the air of the container. A logger taped to the outside of a shipper records the transit environment; a logger buried in the payload records something much closer to what the product experienced, and the two can differ by several degrees for hours.[8]

Simpler devices remain in use and answer narrower questions:

Minimum–maximum thermometers
Record the extremes reached but not their duration, so they cannot support any cumulative calculation.
Chemical threshold indicators
Change colour irreversibly when a threshold is crossed. Freeze indicators of this type are the standard means of detecting a freezing excursion in vaccine distribution.
Time–temperature integrating indicators
Accumulate a colour change as a function of both temperature and time, approximating the cumulative thermal exposure that matters for degradation.
What each monitoring device can and cannot establish
!DeviceEstablishesCannot establish
Electronic data loggerFull time–temperature profile; permits mean kinetic temperatureProduct temperature, unless placed in the payload
Minimum–maximum thermometerExtremes reachedDuration at any temperature
Freeze indicatorThat a freezing threshold was crossedBy how much, or for how long
Time–temperature integratorCumulative exposure above a referenceThe shape of the profile
Vaccine vial monitorCumulative heat exposure at the individual vialFreezing exposure

The vaccine vial monitor deserves separate mention because it is attached to the individual container rather than to the shipment, and therefore survives every custody transfer. It is a heat-sensitive label whose inner square darkens progressively; when it matches or exceeds the reference ring the vial is not to be used. Its limitation is definitional: it responds to heat and not to freezing, so a vial that has been frozen presents an unchanged monitor.[3]

Calibration and traceability

[edit]

A temperature record is only as good as the calibration of the instrument that produced it. Compendial guidance on monitoring devices expects calibration traceable to a national metrology institute, at intervals appropriate to the device, and at points within the range of interest rather than only at ambient temperature. A logger calibrated at 25 °C and used at 5 °C may carry an error larger than its stated accuracy.[8]

The conventional expectation for a logger used in 2–8 °C distribution is an accuracy of ±0.5 °C across that range. This is an expectation drawn from qualification practice and from performance specifications for prequalified devices; it is not a requirement imposed by a general chapter, and articles asserting it as a standard have been corrected on this point.[1][8]

Traceability of the record itself is a separate question from calibration of the sensor. A record that cannot be tied to a specific consignment, with the times of custody transfer identified, cannot be used to attribute an excursion to a stage of the chain, which is the purpose for which such records are chiefly wanted.[9]

References

  1. ^ a b c World Health Organization. "Model guidance for the storage and transport of time- and temperature-sensitive pharmaceutical products." WHO Technical Report Series No. 961, Annex 9 (2011), with associated technical supplements.
  2. ^ Lloyd J, Cheyne J. "The origins of the vaccine cold chain and a glimpse of the future." Vaccine 35(17):2115–2120 (2017).
  3. ^ a b c Kartoglu U, Milstien J. "Tools and approaches to ensure quality of vaccines throughout the cold chain." Expert Review of Vaccines 13(7):843–854 (2014).
  4. ^ Matthias DM, Robertson J, Garrison MM, Newland S, Nelson C. "Freezing temperatures in the vaccine cold chain: a systematic literature review." Vaccine 25(20):3980–3986 (2007).
  5. ^ Hanson CM, George AM, Sawadogo A, Schreiber B. "Is freezing in the vaccine cold chain an ongoing issue? A literature review." Vaccine 35(17):2127–2133 (2017).
  6. ^ a b United States Pharmacopeia, General Chapter <659>, "Packaging and Storage Requirements". USP–NF, current revision.
  7. ^ International Council for Harmonisation, Q1A(R2): Stability Testing of New Drug Substances and Products (2003).
  8. ^ a b c United States Pharmacopeia, General Chapter <1118>, "Monitoring Devices — Time, Temperature, and Humidity" (informational). USP–NF, current revision.
  9. ^ European Commission. Guidelines of 5 November 2013 on Good Distribution Practice of medicinal products for human use (2013/C 343/01). Official Journal of the European Union.